Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Analysis of expression of membrane-bound tumor markers in ductal carcinoma in situ of the breast: paving the way for molecular imaging.

Vermeulen JF, van der Wall E, Witkamp AJ, van Diest PJ.

Cell Oncol (Dordr). 2013 Jul;36(4):333-40. doi: 10.1007/s13402-013-0138-4. Epub 2013 Jun 7.

PMID:
23744486
2.

Differential expression of growth factor receptors and membrane-bound tumor markers for imaging in male and female breast cancer.

Vermeulen JF, Kornegoor R, van der Wall E, van der Groep P, van Diest PJ.

PLoS One. 2013;8(1):e53353. doi: 10.1371/journal.pone.0053353. Epub 2013 Jan 4.

3.

Immunophenotyping invasive breast cancer: paving the road for molecular imaging.

Vermeulen JF, van Brussel AS, van der Groep P, Morsink FH, Bult P, van der Wall E, van Diest PJ.

BMC Cancer. 2012 Jun 13;12:240. doi: 10.1186/1471-2407-12-240.

5.

Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.

Barnes NL, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ.

Clin Cancer Res. 2005 Mar 15;11(6):2163-8.

6.

HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L.

Br J Cancer. 2012 Mar 13;106(6):1160-5. doi: 10.1038/bjc.2012.41. Epub 2012 Feb 23.

7.

Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).

von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, Holms F, Eidtmann H, Dietrich K, Just M, Clemens MR, Hanusch C, Schrader I, Henschen S, Hoffmann G, Tiemann K, Diebold K, Untch M, Denkert C.

Breast Cancer Res Treat. 2012 Apr;132(3):863-70. doi: 10.1007/s10549-011-1621-0. Epub 2011 Jun 12.

PMID:
21667238
8.

Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease.

Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL.

Br J Cancer. 2011 Jan 4;104(1):120-7. doi: 10.1038/sj.bjc.6606021. Epub 2010 Dec 7.

9.

Immunohistochemical categorisation of ductal carcinoma in situ of the breast.

Meijnen P, Peterse JL, Antonini N, Rutgers EJ, van de Vijver MJ.

Br J Cancer. 2008 Jan 15;98(1):137-42. Epub 2007 Nov 27.

10.
11.
12.

Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.

Karlsson E, Sandelin K, Appelgren J, Zhou W, Jirström K, Bergh J, Wärnberg F.

Eur J Cancer. 2014 Feb;50(3):517-24. doi: 10.1016/j.ejca.2013.10.020. Epub 2013 Nov 22.

PMID:
24275214
13.

Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.

Vogl G, Dietze O, Hauser-Kronberger C.

Histopathology. 2005 Dec;47(6):617-24.

PMID:
16324200
14.

Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.

Gonzalez LO, Corte MD, Junquera S, Bongera M, Rodriguez JC, Vizoso FJ.

Histopathology. 2007 Jun;50(7):866-74.

PMID:
17543076
15.

Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery.

Yunes MJ, Neuschatz AC, Bornstein LE, Naber SP, Band V, Wazer DE.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):653-7.

PMID:
12788170
16.

PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Sakr RA, Weigelt B, Chandarlapaty S, Andrade VP, Guerini-Rocco E, Giri D, Ng CK, Cowell CF, Rosen N, Reis-Filho JS, King TA.

Clin Cancer Res. 2014 May 1;20(9):2326-37. doi: 10.1158/1078-0432.CCR-13-2267. Epub 2014 Mar 14.

17.

Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.

Currie MJ, Beardsley BE, Harris GC, Gunningham SP, Dachs GU, Dijkstra B, Morrin HR, Wells JE, Robinson BA.

Hum Pathol. 2013 Mar;44(3):402-11. doi: 10.1016/j.humpath.2012.06.004. Epub 2012 Oct 1.

PMID:
23036368
18.
19.

Underestimation of invasive lesions in patients with ductal carcinoma in situ of the breast diagnosed by ultrasound-guided biopsy: a comparison between patients with and without HER2/neu overexpression.

Chang WC, Hsu HH, Yu JC, Ko KH, Peng YJ, Tung HJ, Chang TH, Hsu GC.

Eur J Radiol. 2014 Jun;83(6):935-41. doi: 10.1016/j.ejrad.2014.02.020. Epub 2014 Mar 2.

PMID:
24666513
20.

The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.

Borgquist S, Zhou W, Jirström K, Amini RM, Sollie T, Sørlie T, Blomqvist C, Butt S, Wärnberg F.

BMC Cancer. 2015 Jun 11;15:468. doi: 10.1186/s12885-015-1479-3.

Items per page

Supplemental Content

Write to the Help Desk